Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Updated: Jun 10, 2026Locations: 3
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. [+12]

Any medical or psychiatric condition that, in the opinion of the Investigator, c... [+4]

Read more
Status: Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Participants needed: 85
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Updated: Jun 11, 2026Locations: 9
Eligibility criteria

Age ≥18 years at the time of signing the informed consent. [+3]

Any medical or psychiatric condition that, in the view of the Principal Investig... [+3]

Read more
Status: Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Participants needed: 230
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Updated: Apr 23, 2026Locations: 13
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status 0-1. [+5]

Active and clinically significant (CS) infection. [+11]

Read more